ARCH Venture Partners

Pioneering Strategies for Technology Commercialization

ARCH Venture Partners invests in the development of seed and early stage advanced technology companies that have the potential to grow rapidly into successful businesses. We invest primarily in companies we co-found with leading scientists and entrepreneurs, concentrating on bringing to market disruptive innovations in life sciences, physical sciences and information technology, and specialize in the spaces where they converge.

We enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions, corporate research groups and national laboratories.

Before the Buzzwords

Our team has deep scientific bench strength to locate and understand nascent technologies long before they grow to become the popular industries of the day. Our first nanotechnology investment was in 1989 (Nanophase Technologies) … our first gene therapy and vaccine investments in 1992 (GenVec and Aviron) … our first digital biology company was founded in 1993 (Illumina) … our first cleantech company in 1994 (Eichrom Technologies) … and our first social networking investment in 1996 ( The buzzwords hadn’t been formed yet, but the science, the technology and the opportunities were all sound.

Partnering Excellence

ARCH has worked with exceptional entrepreneurs as well as academic and industry partners to build more than 180 companies. Among the ARCH-funded companies that are now public firms or were acquired are VBI Vaccines, Pulmatrix, Chiasma, Belleophon Therapeutics, Juno Therapeutics, Illumina, Aviron, Alnylam Pharmaceuticals, Kythera Biopharmaceuticals, Receptos, Agios Pharmaceuticals, Sage Therapeutics, BIND Therapeutics, Fate Therapeutics, Bluebird Bio, Archaogen, Ikaria, Crystal IS, Nanophase Technologies, deCODE Genetics, Celebrate Express, Kotura, NeurogesX, Caliper Life Sciences,, XenoPort, New Era of Networks, Trubion Pharmaceuticals, GenVec, Array BioPharma, Ahura Scientific, ALIS, MicroOptical Devices, Adolor, Everyday Learning, Innovalight, and R2 Technology.

The information on this page may have been provided by a contributor to ChinaGoAbroad, and ChinaGoAbroad makes no guarantees about the accuracy of any content. All content shall be used for informational purposes only. Contributors must obtain all necessary licenses and/or ownership rights from the relevant content owner(s) before submitting such content (including texts, pictures, photos and diagrams) to ChinaGoAbroad for publication. ChinaGoAbroad disclaims all liability arising from the publication of any content/information (such as texts, pictures, photos and diagrams that infringe on any copyright) received from contributors. Links may direct to third party sites out of the control of ChinaGoAbroad, and such links shall not be considered an endorsement by ChinaGoAbroad of any information contained on such third party sites. Please refer to our Disclaimer for more details.


Regions & Countries
Information Technology
Service Areas
Investment Management

Our Team

CLINTON W. BYBEE Co-founder and Managing Director, Austin

Chemicals/Specialty Materials | Electronics/Instrumentation | Semiconductors | Telecommunications | Optics |Nanotechnology | Alternative Energy

KEITH L. CRANDELL Co-founder and Managing Director, Chicago

Chemicals/Specialty Materials | Software | Electronics/Instrumentation | Semiconductors | Telecommunications | Optics | Nanotechnology

STEVEN LAZARUS Co-founder and Managing Director, Emeritus Chicago

ROBERT T. NELSEN Co-founder and Managing Director, Seattle

Biotechnology | Pharmaceuticals | Disruptive Innovation


Chicago, Austin, Seattle, San Francisco, Dublin, Ireland
Email (Jill Williams)
Contact via CGA (Cindy)